Barrantes Francisco J
Biomedical Research Institute (BIOMED), Catholic University of Argentina (UCA)-National Scientific and Technical Research Council, Argentina (CONICET), C1107AFF Buenos Aires, Argentina; email:
Annu Rev Biophys. 2021 May 6;50:493-523. doi: 10.1146/annurev-biophys-102620-080956.
Critical to viral infection are the multiple interactions between viral proteins and host-cell counterparts. The first such interaction is the recognition of viral envelope proteins by surface receptors that normally fulfil other physiological roles, a hijacking mechanism perfected over the course of evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), has successfully adopted this strategy using its spike glycoprotein to dock on the membrane-bound metalloprotease angiotensin-converting enzyme 2 (ACE2). The crystal structures of several SARS-CoV-2 proteins alone or in complex with their receptors or other ligands were recently solved at an unprecedented pace. This accomplishment is partly due to the increasing availability of data on other coronaviruses and ACE2 over the past 18 years. Likewise, other key intervening actors and mechanisms of viral infection were elucidated with the aid of biophysical approaches. An understanding of the various structurally important motifs of the interacting partners provides key mechanistic information for the development of structure-based designer drugs able to inhibit various steps of the infective cycle, including neutralizing antibodies, small organic drugs, and vaccines. This review analyzes current progress and the outlook for future structural studies.
病毒蛋白与宿主细胞对应物之间的多种相互作用对于病毒感染至关重要。首次此类相互作用是病毒包膜蛋白被通常履行其他生理功能的表面受体识别,这是一种在进化过程中完善的劫持机制。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是2019冠状病毒病(COVID-19)的病原体,它成功采用了这种策略,利用其刺突糖蛋白与膜结合金属蛋白酶血管紧张素转换酶2(ACE2)对接。最近以前所未有的速度解析了几种单独的SARS-CoV-2蛋白或与其受体或其他配体形成复合物的晶体结构。这一成果部分归功于过去18年中关于其他冠状病毒和ACE2的数据越来越多。同样,借助生物物理方法阐明了病毒感染的其他关键干预因素和机制。了解相互作用伙伴的各种结构重要基序为开发能够抑制感染周期各个步骤的基于结构的设计药物提供了关键的机制信息,包括中和抗体、有机小分子药物和疫苗。本综述分析了当前的进展以及未来结构研究的前景。